Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).

A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:

1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.

2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.

3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.

4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.

5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding

There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.

How Does Stomach Cancer Spread?

Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.

1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.

2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.

3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.

He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.

The makers of blockbuster weight-loss drugs Novo Nordisk and Eli Lilly are locked in a legal battle after Novo accused its rival of misleading advertising by claiming its obesity and diabetes medicines outperform Novo's treatments.

Danish drugmaker Novo Nordisk has filed a lawsuit against Eli Lilly in the US District Court in New Jersey, alleging the company violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug Zepbound and diabetes treatment Mounjaro, media reports said.

Novo Alleges Ads Used Outdated Comparisons

Novo claims Lilly's advertisements:

• Compared the highest approved doses of Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic.
• Omitted data on the newer 7.2 mg dose of Wegovy, which, as per Novo, delivers greater weight loss.
• Relied on older clinical trial data that no longer reflects current approved dosing.

"The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk's medicines," Novo said in its complaint.

What Did Eli Lilly Say

Eli Lilly rejected the allegations, saying its advertisements accurately reflect findings from its SURMOUNT-5 clinical trial.

According to the company:

• The study, completed in 2024, compared 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg doses of Wegovy.
• Novo's 7.2 mg Wegovy received US FDA approval only in March 2026, after the trial had concluded.

"Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," an Eli Lilly spokesperson said. "We will continue to focus on the science and defend against this lawsuit vigorously."

Battle For Expanding Obesity Market

The lawsuit comes as Novo Nordisk and Eli Lilly compete for dominance in the rapidly expanding US obesity drug market, which analysts expect to exceed $100 billion by 2030.

Both companies dominate the GLP-1 medicine market:

• Novo Nordisk's medicines contain semaglutide.
• Eli Lilly's medicines contain tirzepatide.

These medicines:

• Mimic the GLP-1 hormone.
• Slow digestion.
• Help regulate blood sugar.
• Suppress appetite.

Beyond weight loss, studies have shown that GLP-1 medicines can reduce the risk of major cardiovascular events, including heart attack and stroke, and may also lower the risk of several cancers.

WHO Guidance on GLP-1 Therapies

In December 2025, the World Health Organization (WHO) issued its first guideline on the use of GLP-1 therapies for obesity, describing the condition as a chronic, relapsing disease affecting more than 1 billion people worldwide. It recommends:

• GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women.
• Treatment should be combined with structured lifestyle interventions, including a healthy diet, regular physical activity, and behavioral support to improve outcomes.

Will Patients Be Affected?

For now, patients are unlikely to be affected. The lawsuit does not challenge the safety, effectiveness, or FDA approval of the medicines. Instead, it focuses solely on how Eli Lilly marketed its products.

Patients prescribed the medicines Wegovy and Ozempic (Novo Nordisk) or Zepbound and Mounjaro (Eli Lilly) can continue taking them as directed.

Any outcome of the case is more likely to influence how pharmaceutical companies advertise and compare their medicines than the availability of these treatments.

Paul Alexander woke up inside a 600-pound giant metal tube and never left until he died. Paul depended on an iron lung for every breath, a machine that had largely disappeared from modern medicine.

Known as "the man in the iron lung," Alexander spent more than seven decades living inside the metal cylinder after contracting polio as a child. Paul became a symbol of resilience, determination, and the life-saving power of vaccines. His remarkable story is recalled even after his death in March 2024 at the age of 78.

Who Was Paul Alexander?

The doctors placed him inside an iron lung, a mechanical ventilator that kept him alive by helping his lungs expand and contract.

Although everyone initially believed he might not survive, Alexander defied expectations. He went on to graduate from college, earn a law degree, become a practicing attorney, publish a memoir, and inspire millions through interviews and social media.

Also read: Who Was Martha Lillard? Last U.S. Polio Survivor To Depend On An Iron Lung Who Breathed Her Last At 78

Life Beyond The Iron Lung

Paul Alexander refused to let the machine define him. Doctors taught him a technique called "frog breathing" or glossopharyngeal breathing. By using the muscles of his mouth and throat, he learned to gulp air into his lungs in small amounts.

This helped him to leave the iron lung for short durations, attend school, pursue higher education, and eventually work as a lawyer. Still, he depended on the iron lung for most of his life, especially while sleeping.

Despite his conditions, Alexander earned a bachelor's degree, graduated from law school, practiced as a lawyer in Texas, and wrote his memoir - Three Minutes for a Dog: My Life in an Iron Lung.

His determination challenged and defied assumptions about disability and demonstrated that severe physical limitations need not prevent education, work, or meaningful relationships.

Also read: Even Light Exercise Could Help People With COPD Live Longer, Study Finds

Iron Lung Is An Obsolete Technology In Medicine

An iron lung, also called a negative-pressure ventilator, is a large cylindrical machine that helps people breathe when the muscles controlling respiration become paralyzed.

Unlike today's ventilators, which push air directly into the lungs through a tube or mask using positive pressure, an iron lung works by changing air pressure around the patient's body. The patient lies inside an airtight metal chamber with only the head remaining outside.

The machine then repeatedly lowers the air pressure inside the chamber. This causes the chest to expand naturally, drawing air into the lungs. The pressure then returns to normal. The chest relaxes, allowing air to flow back out. This cycle mimics normal breathing and can continue around the clock.

Iron lungs became obsolete eventually after polio vaccines and modern ventilators were developed.

The introduction of effective polio vaccines in the 1950s and 1960s dramatically reduced cases of paralytic polio worldwide.

The positive-pressure ventilators we use today are smaller, more portable, and better suited to intensive care. They deliver oxygen directly into the lungs, replacing bulky iron lungs.

Paul Alexander's life is more than a remarkable survival story. It serves as a reminder of the devastating impact infectious diseases once had before vaccines transformed public health.

Amid earthquake rescue efforts, Venezuela has reported an outbreak of rat-borne hantavirus that has claimed three lives so far, according to the country's health ministry.

Three people with confirmed hantavirus infection died in the eastern state of Anzoátegui. Two other deaths—both involving health professionals in the state of Barinas—are still under investigation and are not linked to the Anzoátegui cases, the ministry said.

"We report the regrettable deaths of three patients in Anzoátegui with confirmed diagnoses of hantavirus," the ministry said in a statement.

The ministry added that there is "no scientific evidence of person-to-person transmission in our country," noting that the virus is primarily spread by rodents in rural and agricultural areas.

The fresh cases are reported barely two weeks after the World Health Organization (WHO) declared the end of the hantavirus outbreak linked to the MV Hondius luxury expedition ship, which infected 11 people and claimed three lives earlier this year.

What Is Hantavirus?

According to the WHO, hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans. In humans, the infection can cause severe illness and may be fatal, although symptoms vary depending on the virus strain and geographic region.

The virus is primarily transmitted through contact with infected rodents or their urine, droppings, saliva, and, less commonly, through scratches or bites.

According to the CDC, symptoms can appear one to eight weeks after exposure, initially presenting fatigue, fever, and muscle aches. As the disease progresses, it can cause coughing, shortness of breath, and chest tightness as fluid accumulates in the lungs.

Also read: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say

What The Virus Does To The Brain

A recent review published in JAMA Neurology highlights the often-overlooked neurologic complications of hantavirus infection. Hantaviruses cause two major clinical syndromes:

• Hantavirus Pulmonary Syndrome (HPS), seen mainly in the Americas, primarily affects the lungs and cardiovascular system and has a mortality rate of 35% to 50%. Neurologic complications can include headache, delirium, seizures, and, in rare cases, brain hemorrhage or post-viral encephalitis.

• Hemorrhagic Fever with Renal Syndrome (HFRS), which is endemic to Asia and Eastern Russia, presents with fever and kidney involvement and is more commonly associated with direct neurologic complications.

Headaches, Vision Problems, and Hormonal Disorders

Read More: Immunotherapy Shows Early Promise Against Severe Hantavirus Lung Disease: Study

Researchers from the US National Institutes of Health's (NIH) National Institute of Neurological Disorders and Stroke reviewed data from 811 patients infected with the Puumala strain of HFRS.

They found that 97% experienced headaches, 40% reported blurred vision, and 31% experienced vomiting. About 1% developed severe complications such as meningitis or encephalitis, while rare cases involved peripheral neuropathy or stroke.

Pituitary damage was identified as a significant complication of HFRS. It can lead to hormonal disorders weeks or even months after infection. These may include fatigue, adrenal insufficiency, diabetes insipidus, sexual dysfunction, amenorrhea, and symptoms of hypothyroidism.

The studies also reported cerebrospinal fluid abnormalities, sudden vision loss among hantavirus patients.

Long-Term Effects and Treatment

The long-term neurologic consequences of hantavirus remain poorly understood, according to Avindra Nath of the NIH. However, one study found that 20 years after Puumala infection, 78% of patients had persistent hypertension and 8% had chronic kidney disease.

Currently, there are no US Food and Drug Administration (FDA)-approved antiviral treatments or licensed vaccines for hantavirus infection, although several vaccine candidates are in preclinical trials. Several antiviral drugs—including favipiravir, molnupiravir, griffithsin, and ribavirin—have shown promise in early studies, but more research is needed, Nath said.